Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01441128 · ClinicalTrials.gov registry record · Phase 1
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01441128: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01441128 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01441128, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Background: \- PF-02341066 and PF-00299804 are drugs that specifically target certain proteins that may be more active in cancer cells than normal cells, in particular in non-small cell lung cancer. Both drugs seem to be able to stop the growth of or kill cancer cells. Researchers want to combine them to see if they are a safe and effective treatment for advanced non-small cell lung cancer. Objectives: \- To test the safety and effectiveness of PF-02341066 and PF-00299804 for advanced non-small cell lung cancer. Eligibility: \- Individuals at least 18 years of age with advanced non-small cell lung cancer that has not responded to standard treatments. Design: * Participants will be screened with a medical history and physical exam. They will also have blood and urine tests, and imaging studies. Heart and lung function tests and an eye exam may also be given. * The first cycle of treatment will be 28 days. Every cycle after the first will be 21 days. Participants may have up to 17 cycles of treatment. * Participants will take both study drugs as tablets. Twelve hours after the first dose, participants will take only the PF-02341066. This dose schedule will remain the same throughout the study. * Participants will be monitored with frequent blood and urine tests and imaging studies. Tumor biopsies will be taken as needed. Those in the study will keep a diary to record any symptoms or side effects of taking the study drugs. * After 17 cycles of treatment, or after stopping the study drugs early for any other reason, participants will have a final followup visit.
Interventions
- DRUG PF-02341066/PF-00299804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-09-01 |
| Est. Completion | 2015-02-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01441128
The ClinicalTrials.gov registry entry for NCT01441128 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-02341066/PF-00299804 is the first listed.
NCT01441128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01441128 about?
NCT01441128 is a clinical study titled "-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer". Background: \- PF-02341066 and PF-00299804 are drugs that specifically target certain proteins that may be more active in cancer cells than normal cells, in particular in non-small cell lung cancer. Both drugs seem to be able to stop the growth of or kill cancer cells. Researchers want to combine t...
What is the current status of trial NCT01441128?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-09-01. Estimated completion is 2015-02-26.
What interventions are being tested in trial NCT01441128?
The interventions under investigation include: PF-02341066/PF-00299804 (DRUG).
Who is sponsoring clinical trial NCT01441128?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.